NCT02290379View on ClinicalTrials.gov

Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions
Healthy
Interventions
DRUG

TNX-201 35 mg

Drug: TNX-201 35 mg

DRUG

TNX-201 70 mg

Drug: TNX-201 70 mg

DRUG

TNX-201 140 mg

Drug: TNX-201 140 mg

DRUG

Racemic isometheptene 70 mg

Active Comparator: Racemic isometheptene 70 mg

DRUG

Placebo

Drug: Placebo

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT02290379 - Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers | Biotech Hunter | Biotech Hunter